With the business potentially at an important milestone, we thought we'd take a closer look at Glaukos Corporation's (NYSE:GKOS) future prospects. Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The US$5.8b market-cap company announced a latest loss of US$146m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Glaukos' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

According to the 15 industry analysts covering Glaukos, the consensus is that breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$48m in 2027. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 71% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Glaukos' growth isn’t the focus of this broad overview, but, bear in mind that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

See our latest analysis for Glaukos

One thing we’d like to point out is that Glaukos has no debt on its balance sheet, which is rare for a loss-making growth company, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Glaukos which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Glaukos, take a look at Glaukos' company page on Simply Wall St. We've also put together a list of important factors you should further examine:

1. Valuation: What is Glaukos worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Glaukos is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Glaukos’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.